Step-by-Step Guide to Recording Unexpected Adverse Events

What Are Unexpected Adverse Events?

An Unexpected Adverse Event (AE) is any medical occurrence in a clinical trial participant that is not consistent with the Investigator’s Brochure (IB) for investigational products or the approved product labeling (e.g., SmPC or USPI) for marketed drugs. The concept of unexpectedness focuses on whether the nature, severity, or frequency of the event differs from what is described in the reference safety information (RSI). For example, if the IB lists nausea as a common adverse event, but a patient experiences severe pancreatitis not described in the IB, it would be considered unexpected.

Regulatory agencies emphasize this distinction because unexpected events may represent new safety signals. The FDA (21 CFR 312.32) defines unexpected adverse drug experiences as events not listed in the IB, or that differ in severity/frequency. The EMA under EU CTR 536/2014 requires investigators and sponsors to determine expectedness against RSI and classify accordingly. The MHRA in the UK aligns with EMA, while the CDSCO in India mandates that unexpected AEs be notified to ethics committees and reported per ICMR GCP timelines.

Expectedness assessment is critical in expedited reporting. A serious and unexpected AE judged related to the investigational product is classified as a SUSAR (Suspected Unexpected Serious Adverse Reaction), triggering 7- or 15-day reporting timelines. Proper classification therefore impacts regulatory compliance, patient safety, and the continuation of trials without unnecessary delays.

Decision Framework for Recording Unexpected AEs

Investigators and sponsors should follow a structured approach to recording unexpected AEs:

1. Identify the event: Record onset date, symptoms, signs, labs, or imaging abnormalities.
2. Check seriousness: Determine whether hospitalization, death, disability, or medical significance criteria are met.
3. Assess causality: Investigator judgment on whether the event is related to investigational product or procedure.
4. Determine expectedness: Compare to IB/SmPC. If the event is not listed, or its severity/frequency is beyond what is described, it is unexpected.
5. Document in CRF/EDC: Record severity (CTCAE grade if applicable), seriousness, causality, and expectedness.
6. Trigger reporting: If serious, unexpected, and related → SUSAR → expedited report to regulators within required timelines.

Unexpected AEs must be entered promptly into electronic data capture systems. Sponsors should embed edit checks requiring investigators to specify the rationale for expectedness assessment. For multicenter trials, central pharmacovigilance teams should harmonize classification across sites to avoid inconsistencies that inspectors may flag during audits.

Oncology-Specific Examples of Unexpected AEs

Oncology trials, given their complexity, frequently encounter unexpected AEs. Consider the following examples:

• Case 1: A patient on an anti-PD-1 agent develops immune-mediated myocarditis. This is unexpected if the IB lists only colitis, hepatitis, and pneumonitis as known immune toxicities. Classification: SAE, unexpected, related → SUSAR.
• Case 2: A subject on cisplatin develops ototoxicity (hearing loss). If the IB/label describes nephrotoxicity and neuropathy but not ototoxicity, this is unexpected. Classification: AE, unexpected; serious if hospitalization or disability occurs.
• Case 3: A patient in a breast cancer trial develops autoimmune thyroiditis. If thyroiditis is not described in IB, classify as unexpected and potentially serious if it causes hospitalization or disability.

These oncology cases highlight the importance of aligning with the most current IB version. Sponsors must ensure updated RSI is provided to all investigators, and that ongoing safety signals are reflected promptly in amendments.

Sample Recording Table for Unexpected AEs

Note: Classification must always consider causality and seriousness alongside expectedness. Documentation of rationale is critical for inspection readiness.

Regulatory Expectations for Unexpected AEs

Different agencies provide harmonized but nuanced guidance:

• FDA: Requires expedited reporting of unexpected serious adverse reactions (SUSARs). Safety updates must summarize unexpected AEs across all INDs.
• EMA: Unexpectedness judged against RSI in the IB. SAE + unexpected + related events → expedited EudraVigilance reporting.
• MHRA: Post-Brexit, UK-specific pharmacovigilance timelines apply. Still aligns broadly with EMA principles.
• CDSCO (India): Unexpected AEs must be reported within 24 hours to sponsors and ethics committees. SAE committees review causality and regulatory reporting compliance.

These rules mean sponsors must harmonize expectedness assessment globally while adhering to local expedited timelines. Discrepancies in expectedness judgment across sites or regions can create inspection findings and undermine trial credibility.

Documentation Practices and Narratives

Unexpected AEs require rigorous documentation. Narratives should include:

• Baseline patient characteristics and comorbidities.
• Chronology of dosing, event onset, and interventions.
• Severity grade and seriousness criteria.
• Reference to IB/label showing absence of event description.
• Investigator’s causality assessment and sponsor’s review.
• Outcome and follow-up information.

Inspectors often focus on whether expectedness determination is clearly justified in narratives. Sponsors should require investigators to cite IB/SmPC sections during documentation to support regulatory compliance.

Case Study: Unexpected AE in Oncology

Scenario: A patient in a Phase II melanoma trial on checkpoint inhibitor develops myocarditis with troponin elevation, ECG changes, and dyspnea. IB lists colitis, pneumonitis, hepatitis as immune-related events but not myocarditis.

• Seriousness: Yes, due to hospitalization and risk of death.
• Severity: Grade 3, life-threatening if unmanaged.
• Expectedness: Not in IB → unexpected.
• Causality: Likely related to immunotherapy.
• Classification: SUSAR.
• Reporting: Expedited within 7 days to FDA/EMA; to CDSCO within 24 hours of knowledge.

Learning point: Sponsors must ensure RSI is regularly updated. If emerging class effects such as myocarditis are identified, they must be added to IB to prevent ongoing misclassification as unexpected.

Inspection Readiness for Unexpected AE Reporting

Auditors often highlight gaps in unexpected AE reporting. Common findings include:

• Investigators failing to assess expectedness correctly.
• Discrepancies between EDC entries and safety database classification.
• Lack of justification for expectedness in SAE forms and narratives.
• Delayed expedited reports due to sponsor–site miscommunication.

To address these, sponsors should establish:

• Expectedness SOPs: Standardized criteria for determining unexpectedness.
• Central PV review: Sponsor medical safety officers to confirm expectedness classification.
• EDC edit checks: Mandatory fields requiring expectedness rationale.
• Training modules: Regular refresher courses for site staff using case studies.

Additionally, cross-functional reconciliation between clinical operations and pharmacovigilance ensures that unexpected AEs are consistently captured, reported, and archived for inspections.

Key Takeaways for Clinical Teams

Unexpected AEs are more than just anomalies—they are potential early warning signals of new safety risks. Professionals should:

• Differentiate severity, seriousness, and expectedness clearly.
• Apply consistent global criteria using the IB or SmPC as reference.
• Document justifications in CRFs, narratives, and safety databases.
• Update RSI promptly to reflect emerging class effects.
• Train staff regularly on case-based examples in oncology and beyond.

By recording unexpected AEs rigorously, sponsors and investigators ensure patient safety, regulatory compliance, and scientific credibility across trials in the US, EU, UK, and India.